Open AccessThe putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients
Author(s) -
Lukasz Szafron,
Anna Balcerak,
Ewa Grzybowska,
Barbara Pieńkowska-Grela,
Agnieszka Podgorska,
Renata Zub,
Magdalena Olbryt,
Jolanta PamułaPiłat,
Katarzyna Lisowska,
Tymon Rubel,
Agnieszka Dansonka-Mieszkowska,
B Konopka,
Magdalena Kulesza,
Martyna Łukasik,
Jolanta Kupryjańczyk
Publication year - 2015
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.6016
Subject(s) - ovarian cancer , medicine , oncology , cancer research , oncogene , cancer , tissue microarray , gene expression profiling , gene , gene expression , biology , cell cycle , genetics
The CRNDE gene seems to play an oncogenic role in cancers, though its exact function remains unknown. Here, we tried to assess its usefulness as a molecular prognostic marker in ovarian cancer. Based on results of our microarray studies, CRNDE transcripts were further analyzed by Real-Time qPCR-based profiling of their expression. The qPCR study was conducted with the use of personally designed TaqMan assays on 135 frozen tissue sections of ovarian carcinomas from patients treated with platinum compounds and either cyclophosphamide (PC, N = 32) or taxanes (TP, N = 103). Elevated levels of two different CRNDE transcripts were a negative prognostic factor; they increased the risk of death and recurrence in the group of patients treated with TP, but not PC (DNA-damaging agents only). Higher associations were found for overexpression of the short CRNDE splice variant (FJ466686): HR 6.072, 95% CI 1.814-20.32, p = 0.003 (the risk of death); HR 15.53, 95% CI 3.812-63.28, p < 0.001 (the risk of recurrence). Additionally, accumulation of the TP53 protein correlated with decreased expression of both CRNDE transcripts in tumor cells. Our results depict CRNDE as a potential marker of poor prognosis in women with ovarian carcinomas, and suggest that its significance depends on the therapeutic regimen used.